Seagen Inc. with ticker code (SGEN) now have 12 market analysts covering the stock. The analyst consensus now points to a rating of ‘hold’. The target price High/Low ranges between 229 and 180 suggesting an average Analsyt target price of $224.83. Given that the stocks previous close was at $207.18 this would imply there is now a potential upside of 8.5%. The 50 day moving average now sits at $196.04 and the 200 day MA is $175.36. The total market capitalization for the company now stands at 38.68B. The stock price for the company is currently is currently 206.1 USD
The potential market cap would be $41,980,157,450 based on the market consensus.
The company has a dividend yield of 5.95%. Other points of data to note are a P/E ratio of -, revenue per share of 11.6 and a -12.56% return on assets.
Seagen Inc. is a biotechnology company that develops and commercializes targeted therapies to treat cancer. The Company is engaged in commercializing ADCETRIS, or brentuximab vedotin, for the treatment of certain CD30-expressing lymphomas; PADCEV, or enfortumab vedotin-ejfv, for the treatment of certain metastatic urothelial cancers; TUKYSA, or tucatinib, for the treatment of certain metastatic human epidermal growth factor receptor 2 (HER2) -positive breast and colorectal cancers, and TIVDAK, or tisotumab vedotin-tftv, for the treatment of certain metastatic cervical cancers. It is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers designed to address unmet medical needs and improve treatment outcomes for patients. Its programs including ADCETRIS, PADCEV and TIVDAK, are based on the Company’s antibody-drug conjugate (ADC) technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells.
